NEW YORK, July 28, 2015 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B (HBV) and hepatitis D (HDV) infection, today announced that it will be participating in the Jefferies Hepatitis B summit to be held August 6, 2015 in Boston. This summit brings together companies developing state of the art antiviral technologies targeting HBV and thought leaders to discuss the future of treatment for chronic HBV infection.
Replicor will present an up to date overview of its clinical development program for its nucleic acid polymer (NAP) technology and the potential for achieving high rates of SVR in patients with chronic HBV infection and HBV / HDV co-infection.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV infection. For further information about Replicor please visit our website at www.replicor.com and follow us on Twitter @replicorinc.